uniQure to Participate in Multiple Upcoming Industry Conferences
January 30, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
December 03, 2018 07:00 ET
|
uniQure Inc.
-- Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and a Half Years of Follow-up – -- Second Dose Cohort Demonstrated a 93% Reduction in FIX Replacement Therapy Usage During...
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
November 15, 2018 07:00 ET
|
uniQure Inc.
~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~ ~ None of the Patients Received Factor Infusions,...
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
September 24, 2018 07:00 ET
|
uniQure Inc.
~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
August 23, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 23, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
June 28, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
May 29, 2018 07:00 ET
|
uniQure Inc.
~ Newly Issued Patents in the U.S. and Canada Cover Methods of Treating Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy ~ ~ Additional Issued Patent Covering...